GangaGen

GangaGen, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapeutic proteins for infectious diseases in areas of high unmet need, such as MRSA and other drug-resistant bacteria. Using a proprietary platform, GangaGen is developing highly specific therapeutic proteins called ectolysins to target clinically significant types of bacteria.The company's lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA).